Forbes January 3, 2025
Respiratory syncytial virus activity continues to rise in the United States, according to the latest weekly update from the Centers for Disease Control and Prevention, with an increasing number of children being hospitalized across most of the country.
A United States-based study published in November 2024 demonstrated that a recently approved vaccine, nirsevimab, was 80% effective against hospitalizations in non-immunocompromised individuals aged 60 and older. And phase 3 trial data released in the fall showed that nirsevimab cut RSV hospitalizations in healthy full-term and near-full-term infants by 77%.
RSV is the second leading cause of deaths worldwide in children under 5 years old, after malaria. RSV causes 118,000 deaths in this age group each year. The virus is also the...
Today's Sponsors
Today's Sponsor